Oxford BioMedica (OTCMKTS:OXBDF) Sees Large Volume Increase – Still a Buy?

Shares of Oxford BioMedica (OTCMKTS:OXBDFGet Free Report) saw strong trading volume on Monday . 17,020 shares changed hands during mid-day trading, an increase of 347% from the previous session’s volume of 3,810 shares.The stock last traded at $11.30 and had previously closed at $11.1920.

Oxford BioMedica Stock Up 0.6%

The company has a debt-to-equity ratio of 3.08, a quick ratio of 1.67 and a current ratio of 1.89. The firm has a 50-day moving average price of $9.83 and a two-hundred day moving average price of $8.37.

Oxford BioMedica Company Profile

(Get Free Report)

Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.

In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.

Featured Articles

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.